ZYMEWORKS INC. Forum: Community User: Karmate1

https://www.businesswire.com/news/home/20220912005256/en/Zymeworks-Reports-Preliminary-Phase-1-Trial-Results-for-Zanidatamab-Zovodotin-ZW49-at-European-Society-for-Medical-Oncology-Annual-Congress

https://www.businesswire.com/news/home/20220908005502/en/Zymeworks-Announces-Filing-and-Mailing-of-Materials-for-the-Special-Meeting-to-Approve-Redomicile-to-Delaware

https://seekingalpha.com/news/3880545-zymeworks-plunges-20-after-phase-1-data-for-cancer-candidate?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain

https://www.businesswire.com/news/home/20220904005028/en/Zymeworks-Announces-Release-of-ESMO-Abstract-for-Phase-1-Study-of-Zanidatamab-Zovodotin-ZW49-in-Solid-Cancers

Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-provides-corporate-update-and-reports-second-quarter

https://www.businesswire.com/news/home/20220725005250/en/Zymeworks-Announces-Oral-Presentation-of-Data-from-Phase-1-Study-of-Zanidatamab-Zovodotin-ZW49-in-Solid-Cancers-at-European-Society-for-Medical-Oncology-ESMO-Congress-2022-in-Paris

Zymeworks Announces Plan to Become a Delaware Corporation https://www.businesswire.com/news/home/20220715005061/en/Zymeworks-Announces-Plan-to-Become-a-Delaware-Corporation • Enhances alignment with US shareholder base and other peer biotechnology companies • Positions company for growth while helping to reduce complexity and certain administrative costs • The Company’s name, brand, and ticker symbol to remain unchanged ...

🍀

☕️

https://www.businesswire.com/news/home/20220627005177/en/Zymeworks-Appoints-Dr.-Paul-Moore-as-Chief-Scientific-Officer

https://finance.yahoo.com/news/zymeworks-adopts-limited-duration-shareholder-131500847.html

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022 https://www.businesswire.com/news/home/20220526005690/en/Clinical-Data-Demonstrating-Promising-Antitumor-Activity-with-Zanidatamab-in-1L-Setting-of-HER2%E2%80%91Positive-Breast-and-Gastroesophageal-Cancers-to-be-Presented-at-ASCO-2022 • Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer • Zanidatamab in combination with chemotherapy and tislelizumab shows 75.8% cORR and 100% disease control rate (DCR) in first-line treatment of advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma

Zymeworks jumps after bidder All Blue Falcons raises state, promising data ahead of ASCO conference (update) https://seekingalpha.com/news/3843300-zymeworks-gains-after-bidder-all-blue-falcons-raises-stake Zymeworks (NYSE:ZYME) soared 10% in after hours trading after investment firm All Blue Falcons raised its stake in the oncology oncology maker after its $10.50/share offer was rejected last Friday. The company also reported "promising" data ahead of an ASCO presentation. All Blue Falcons boosted its stake to 6.9% and now owns just under 4m shares and options, according to a 13D/A filing Zymeworks (ZYME) separately reported clinical data demonstrating "promising" antitumor activity with Zanidatamab in 1L Setting of HER2‑Positive breast and gastroesophageal cancers, according to a statement. The data comes ahead of ZYME's appearance at the ASCO conference next week. ...

https://www.defenseworld.net/2022/05/23/hc-wainwright-cuts-zymeworks-nysezyme-price-target-to-40-00.html

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal https://www.businesswire.com/news/home/20220520005056/en/Zymeworks%E2%80%99-Board-of-Directors-Unanimously-Rejects-Unsolicited-Non-Binding-Proposal